Effects of opioid receptor blockade on luteinizing hormone (LH) pulses and interpulse LH concentrations in normal women during the early phase of the menstrual cycle

W. S. Evans, J. Y. Weltman, M. L. Johnson, A. Weltman, Johannes D Veldhuis, A. D. Rogol

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To determine the role of endogenous opioid peptides in regulating pulsatile luteinizing hormone (LH) release in the early follicular phase of the menstrual cycle of eumenorrheic women, we evaluated serum LH concentrations in blood collected every 10 min for 12 h in 27 women each studied during two menstrual cycles: (1) without pretreatment and (2) following oral administration of naltrexone, a mu opiate receptor blocking agent, at a dose of 1.0 mg/kg. Pulsatile LH release was assessed by the CLUSTER algorithm. The mean (±SE) integrated serum LH concentration (IU/L/min) increased following the administration of naltrexone (4715±298) in comparison to the control day (3997±381; p=0.0008). The mean number of LH pulses (/12 h) detected on the naltrexone day (10.3±0.3) was higher than on the control day (8.9±0.4; p=0.0068). Mean maximal LH peak height (IU/L) was greater on the naltrexone (7.8±0.5) vs control (6.7±0.5) days (p=0.0064) as was the interpulse valley mean serum LH concentration (IU/L; 6.3±0.4 vs 5.0±0.4; p=0.0013). No difference was noted in the mean incremental LH pulse amplitude (IU/L; 1.9±0.1 vs 2.1±0.1; p=0.13), or peak duration (min; 40±1.8 vs 45.0±2.4; p=0.06). Mean LH peak area (IU/L/min) was greater on the control (45.0±2.4) vs naltrexone (40±1.8) days (p=0.0475). These results suggest that inhibition of endogenous opioid peptide systems with naltrexone in the early follicular phase of the menstrual cycle is associated with an alteration of the gonadotropin-releasing hormone (GnRH) pulse generator firing rate as appraised indirectly by enumeration of distinct LH pulses. The enhanced maximal serum LH pulse amplitude and interpulse valley mean LH concentrations, together with no observed change in the incremental amplitude, suggest a naltrexone-associated augmentation of low levels of basal LH release, a skewing of LH secretory burst waveform, and/or a prolongation of LH half-life.

Original languageEnglish (US)
Pages (from-to)525-531
Number of pages7
JournalJournal of Endocrinological Investigation
Volume15
Issue number7
StatePublished - 1992
Externally publishedYes

Fingerprint

Opioid Receptors
Menstrual Cycle
Luteinizing Hormone
Naltrexone
Follicular Phase
Opioid Peptides
Serum
mu Opioid Receptor
Gonadotropin-Releasing Hormone
Oral Administration
Half-Life

Keywords

  • Early follicular phase
  • LH pulses
  • Opioid antagonists

ASJC Scopus subject areas

  • Endocrinology

Cite this

Effects of opioid receptor blockade on luteinizing hormone (LH) pulses and interpulse LH concentrations in normal women during the early phase of the menstrual cycle. / Evans, W. S.; Weltman, J. Y.; Johnson, M. L.; Weltman, A.; Veldhuis, Johannes D; Rogol, A. D.

In: Journal of Endocrinological Investigation, Vol. 15, No. 7, 1992, p. 525-531.

Research output: Contribution to journalArticle

Evans, W. S. ; Weltman, J. Y. ; Johnson, M. L. ; Weltman, A. ; Veldhuis, Johannes D ; Rogol, A. D. / Effects of opioid receptor blockade on luteinizing hormone (LH) pulses and interpulse LH concentrations in normal women during the early phase of the menstrual cycle. In: Journal of Endocrinological Investigation. 1992 ; Vol. 15, No. 7. pp. 525-531.
@article{e5750541477d497ab89ef6ad41514c80,
title = "Effects of opioid receptor blockade on luteinizing hormone (LH) pulses and interpulse LH concentrations in normal women during the early phase of the menstrual cycle",
abstract = "To determine the role of endogenous opioid peptides in regulating pulsatile luteinizing hormone (LH) release in the early follicular phase of the menstrual cycle of eumenorrheic women, we evaluated serum LH concentrations in blood collected every 10 min for 12 h in 27 women each studied during two menstrual cycles: (1) without pretreatment and (2) following oral administration of naltrexone, a mu opiate receptor blocking agent, at a dose of 1.0 mg/kg. Pulsatile LH release was assessed by the CLUSTER algorithm. The mean (±SE) integrated serum LH concentration (IU/L/min) increased following the administration of naltrexone (4715±298) in comparison to the control day (3997±381; p=0.0008). The mean number of LH pulses (/12 h) detected on the naltrexone day (10.3±0.3) was higher than on the control day (8.9±0.4; p=0.0068). Mean maximal LH peak height (IU/L) was greater on the naltrexone (7.8±0.5) vs control (6.7±0.5) days (p=0.0064) as was the interpulse valley mean serum LH concentration (IU/L; 6.3±0.4 vs 5.0±0.4; p=0.0013). No difference was noted in the mean incremental LH pulse amplitude (IU/L; 1.9±0.1 vs 2.1±0.1; p=0.13), or peak duration (min; 40±1.8 vs 45.0±2.4; p=0.06). Mean LH peak area (IU/L/min) was greater on the control (45.0±2.4) vs naltrexone (40±1.8) days (p=0.0475). These results suggest that inhibition of endogenous opioid peptide systems with naltrexone in the early follicular phase of the menstrual cycle is associated with an alteration of the gonadotropin-releasing hormone (GnRH) pulse generator firing rate as appraised indirectly by enumeration of distinct LH pulses. The enhanced maximal serum LH pulse amplitude and interpulse valley mean LH concentrations, together with no observed change in the incremental amplitude, suggest a naltrexone-associated augmentation of low levels of basal LH release, a skewing of LH secretory burst waveform, and/or a prolongation of LH half-life.",
keywords = "Early follicular phase, LH pulses, Opioid antagonists",
author = "Evans, {W. S.} and Weltman, {J. Y.} and Johnson, {M. L.} and A. Weltman and Veldhuis, {Johannes D} and Rogol, {A. D.}",
year = "1992",
language = "English (US)",
volume = "15",
pages = "525--531",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Editrice Kurtis s.r.l.",
number = "7",

}

TY - JOUR

T1 - Effects of opioid receptor blockade on luteinizing hormone (LH) pulses and interpulse LH concentrations in normal women during the early phase of the menstrual cycle

AU - Evans, W. S.

AU - Weltman, J. Y.

AU - Johnson, M. L.

AU - Weltman, A.

AU - Veldhuis, Johannes D

AU - Rogol, A. D.

PY - 1992

Y1 - 1992

N2 - To determine the role of endogenous opioid peptides in regulating pulsatile luteinizing hormone (LH) release in the early follicular phase of the menstrual cycle of eumenorrheic women, we evaluated serum LH concentrations in blood collected every 10 min for 12 h in 27 women each studied during two menstrual cycles: (1) without pretreatment and (2) following oral administration of naltrexone, a mu opiate receptor blocking agent, at a dose of 1.0 mg/kg. Pulsatile LH release was assessed by the CLUSTER algorithm. The mean (±SE) integrated serum LH concentration (IU/L/min) increased following the administration of naltrexone (4715±298) in comparison to the control day (3997±381; p=0.0008). The mean number of LH pulses (/12 h) detected on the naltrexone day (10.3±0.3) was higher than on the control day (8.9±0.4; p=0.0068). Mean maximal LH peak height (IU/L) was greater on the naltrexone (7.8±0.5) vs control (6.7±0.5) days (p=0.0064) as was the interpulse valley mean serum LH concentration (IU/L; 6.3±0.4 vs 5.0±0.4; p=0.0013). No difference was noted in the mean incremental LH pulse amplitude (IU/L; 1.9±0.1 vs 2.1±0.1; p=0.13), or peak duration (min; 40±1.8 vs 45.0±2.4; p=0.06). Mean LH peak area (IU/L/min) was greater on the control (45.0±2.4) vs naltrexone (40±1.8) days (p=0.0475). These results suggest that inhibition of endogenous opioid peptide systems with naltrexone in the early follicular phase of the menstrual cycle is associated with an alteration of the gonadotropin-releasing hormone (GnRH) pulse generator firing rate as appraised indirectly by enumeration of distinct LH pulses. The enhanced maximal serum LH pulse amplitude and interpulse valley mean LH concentrations, together with no observed change in the incremental amplitude, suggest a naltrexone-associated augmentation of low levels of basal LH release, a skewing of LH secretory burst waveform, and/or a prolongation of LH half-life.

AB - To determine the role of endogenous opioid peptides in regulating pulsatile luteinizing hormone (LH) release in the early follicular phase of the menstrual cycle of eumenorrheic women, we evaluated serum LH concentrations in blood collected every 10 min for 12 h in 27 women each studied during two menstrual cycles: (1) without pretreatment and (2) following oral administration of naltrexone, a mu opiate receptor blocking agent, at a dose of 1.0 mg/kg. Pulsatile LH release was assessed by the CLUSTER algorithm. The mean (±SE) integrated serum LH concentration (IU/L/min) increased following the administration of naltrexone (4715±298) in comparison to the control day (3997±381; p=0.0008). The mean number of LH pulses (/12 h) detected on the naltrexone day (10.3±0.3) was higher than on the control day (8.9±0.4; p=0.0068). Mean maximal LH peak height (IU/L) was greater on the naltrexone (7.8±0.5) vs control (6.7±0.5) days (p=0.0064) as was the interpulse valley mean serum LH concentration (IU/L; 6.3±0.4 vs 5.0±0.4; p=0.0013). No difference was noted in the mean incremental LH pulse amplitude (IU/L; 1.9±0.1 vs 2.1±0.1; p=0.13), or peak duration (min; 40±1.8 vs 45.0±2.4; p=0.06). Mean LH peak area (IU/L/min) was greater on the control (45.0±2.4) vs naltrexone (40±1.8) days (p=0.0475). These results suggest that inhibition of endogenous opioid peptide systems with naltrexone in the early follicular phase of the menstrual cycle is associated with an alteration of the gonadotropin-releasing hormone (GnRH) pulse generator firing rate as appraised indirectly by enumeration of distinct LH pulses. The enhanced maximal serum LH pulse amplitude and interpulse valley mean LH concentrations, together with no observed change in the incremental amplitude, suggest a naltrexone-associated augmentation of low levels of basal LH release, a skewing of LH secretory burst waveform, and/or a prolongation of LH half-life.

KW - Early follicular phase

KW - LH pulses

KW - Opioid antagonists

UR - http://www.scopus.com/inward/record.url?scp=0026640507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026640507&partnerID=8YFLogxK

M3 - Article

C2 - 1447490

AN - SCOPUS:0026640507

VL - 15

SP - 525

EP - 531

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 7

ER -